Lynparza Breast Cancer Clinical Experience Investigation
Completed
- Conditions
- Breast Cancer
- Registration Number
- NCT03590938
- Lead Sponsor
- AstraZeneca
- Brief Summary
To characterise the development of ADRs of bone marrow depression in patients under actual post-marketing use
- Detailed Description
To characterise the development of adverse drug reactions (ADRs) of bone marrow depression in patients with unresectable or recurrent BRCA mutated HER2 negative breast cancer who have previously received anticancer chemotherapy under actual post-marketing use.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 111
Inclusion Criteria
- Unresectable or recurrent BRCA mutated HER2 negative breast cancer with prior anticancer chemotherapy
Exclusion Criteria
- The patients who are not started on Lymparza for the first time
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Adverse drug reactions of bone marrow depression One year period Bone marrow depression will be investigated as safety specification topics
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Research Site
🇯🇵Yamaguchi, Japan